Cartesian Therapeutics (RNAC) Accumulated Depreciation & Amortization (2016 - 2025)
Cartesian Therapeutics (RNAC) has disclosed Accumulated Depreciation & Amortization for 11 consecutive years, with $3.5 million as the latest value for Q2 2025.
- On a quarterly basis, Accumulated Depreciation & Amortization fell 41.62% to $3.5 million in Q2 2025 year-over-year; TTM through Jun 2025 was $3.5 million, a 41.62% decrease, with the full-year FY2024 number at $2.4 million, down 58.85% from a year prior.
- Accumulated Depreciation & Amortization was $3.5 million for Q2 2025 at Cartesian Therapeutics, up from $2.9 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $6.3 million in Q3 2024 to a low of $2.4 million in Q4 2024.
- A 5-year average of $4.8 million and a median of $5.0 million in 2022 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: grew 15.68% in 2023, then plummeted 58.85% in 2024.
- Cartesian Therapeutics' Accumulated Depreciation & Amortization stood at $4.8 million in 2021, then increased by 8.51% to $5.2 million in 2022, then rose by 10.05% to $5.7 million in 2023, then tumbled by 58.85% to $2.4 million in 2024, then surged by 49.34% to $3.5 million in 2025.
- Per Business Quant, the three most recent readings for RNAC's Accumulated Depreciation & Amortization are $3.5 million (Q2 2025), $2.9 million (Q1 2025), and $2.4 million (Q4 2024).